CQN-MA-RENAGADE
29.4.2024 23:01:34 CEST | Business Wire | Press release
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions.
The updated release reads:
RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY
GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A.
Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel glycobiology
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to unlock the potential of glycobiology through support for ongoing research at GanNA Bio, and an integration of the key founders of GanNA Bio into the ReNAgade ecosystem.
GanNA Bio was formed in 2021 and invested in by ReNAgade to harness novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center, which was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D., M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and to unlock the delivery of short and long stranded RNA medicines.
“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” GanNA founders Bertozzi and Cummings will now serve as advisors to ReNAgade.
“The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases of RNA medicines,” said Ryan Flynn.
Dr. Bertozzi added, “The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients.” Dr. Cummings noted that “Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider med samarbejdsfirmaet Saratoga Software4.2.2026 18:43:00 CET | Pressemeddelelse
Andersen Consulting styrker sit udbud inden for digital transformation med tilføjelsen af samarbejdspartneren Saratoga Software, en leverandør af softwareleverancer og specialiserede teknologiløsninger. Saratoga Software blev grundlagt i 1998 og tilbyder virksomheder, især inden for den finansielle sektor og fintech-branchen, en omfattende række tjenester, herunder specialudviklede softwareløsninger, forretningsanalyse, platformsintegration og support, kvalitetssikring, projektledelse samt data engineering og business intelligence. Med kontorer i Sydafrika og Storbritannien specialiserer firmaet sig også i løsninger inden for ai og machine learning samt cloud-migrering, kundekommunikationsstyring og strategisk teknologirådgivning. "Vores team besidder dyb ingeniørfaglig ekspertise, anciennitet og en dokumenteret evne til at løse komplekse problemer – kvaliteter, der gør os til betroede rådgivere for vores kunder," udtalte Anthony Robinson, bestyrelsesformand for Saratoga Software. "At
InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 18:00:00 CET | Press release
Recognized for excellence in Acute Care EHR and Shared Care Records across Asia, Oceania, and Europe InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recogni
Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 16:00:00 CET | Press release
Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva
Energy Vault announces the Award of 100 MW / 870 MWh Long-Term Energy Service Agreement to its Development Partner in Australia4.2.2026 15:09:00 CET | Press release
Energy Vault’s development partner in Australia, Bridge Energy, has secured a 14-year Long-Term Energy Service Agreement (LTESA) for the EBOR Battery Energy Storage System (BESS) project (100 MW / 870 MWh), under the NSW Electricity Infrastructure RoadmapEnergy Vault holds the exclusive option to acquire and construct the A$310 million project having supported Bridge through early stage developmentThe project will feature Energy Vault’s proprietary B-VAULT™ technology and Vault-OS™ Energy Management System software to provide essential grid firming capacityEnergy Vault acquired the Stoney Creek 125 MW / 1,000 MWh project in New South Wales in 2025, which also holds an LTESA, as Energy Vault rapidly expands its Australian footprint Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault”), a leader in sustainable, grid-scale energy storage solutions, and Bridge Energy Pty Ltd (“Bridge Energy”), an Australian developer bridging the gap between fossil fuels and renewable energy, today ann
Ground Investigation for Civil Infrastructure Gets More Robust With Integration of Lab and Field Geotechnical Data4.2.2026 15:00:00 CET | Press release
Major update to leading geotechnical data management solution OpenGround, enables organisations to digitise geotechnical lab testing, enhancing efficiency and collaboration across engineering teams Seequent, The Bentley Subsurface Company, has streamlined laboratory testing in OpenGround, the leading cloud-connected geotechnical data management solution. The new OpenGround Labs capability enables seamless transfer of soil and rock sample data from field collection to laboratory testing and reporting, with results delivered directly to engineers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204539856/en/ Geotechnical labs can generate Atterberg limits test certificates from raw lab test data in OpenGround. The advancement enables an end-to-end digital engineering-to-lab workflow, enhancing collaboration and improving efficiency between ground investigation and laboratory testing teams. “Trusted Lab testing data is vital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom